SAN DIEGO, Aug. 7, 2013 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) today announced the closing of its
previously announced underwritten public offering of 9,000,000
shares of its common stock, as well as 1,350,000 additional shares
of its common stock pursuant to the full exercise of the
over-allotment option granted to the underwriters.
The shares were sold at the public offering price of
$4.50 per share and the company
estimates the aggregate net proceeds to the company will be
approximately $43.3 million, after
deducting underwriting discounts and commissions and other
estimated offering expenses.
Lazard Capital Markets LLC and Oppenheimer & Co. Inc. acted
as joint book-runners for the offering. JMP Securities LLC and
Maxim Group LLC served as co-managers for the offering.
The shares described above were issued pursuant to a prospectus
supplement and accompanying prospectus, all as filed as part of a
shelf registration statement on Form S-3 previously filed with and
declared effective by the Securities and Exchange Commission
("SEC"). Copies of the prospectus supplement and the accompanying
prospectus may be obtained by sending a request to: Lazard Capital
Markets LLC, at 30 Rockefeller Plaza, New
York, NY 10020 or via telephone at (800) 542-0970, or
Oppenheimer & Co. Inc., Attn: Syndicate Department, at 85 Broad
Street, 26th Floor, New York, NY
10004 or via email at equityprospectus@opco.com or via telephone at
(212) 667-8563. The company filed a final prospectus supplement
relating to the offering with the SEC on August 2, 2013, which is available along with the
accompanying prospectus filed with the SEC in connection with the
shelf registration, on the SEC's website at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of Organovo, nor
shall there be any sale of securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of
any such state or jurisdiction. This press release is being issued
pursuant to and in accordance with Rule 134 under the Securities
Act of 1933, as amended.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
company is collaborating with pharmaceutical and academic partners
to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. In addition to numerous scientific publications,
their technology has been featured in The Wall Street Journal, Time
Magazine, The Economist, and numerous others. Organovo is changing
the shape of medical research and practice. Learn more at
www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including the
prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form
10-KT filed with the SEC on May 24,
2013 and our other filings with the Securities and Exchange
Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date that
they were made. These cautionary statements should be considered
with any written or oral forward-looking statements that we may
issue in the future. Except as required by applicable law,
including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.
